Pohled na současnou postgraduální přípravu lékařů

JUDr. Pavel Janda

Psychiatr. praxi 2017; 18(3): 95  

Long-acting injectable antipsychotics in clinical practice

MUDr. Bc. Libor Ustohal, Ph.D.

Psychiatr. praxi 2017; 18(3)  

The article summarizes basic data concerning long-acting injectable or depot antipsychotics, which are currently available in theCzech Republic. They include four first generation antipsychotics (fluphenazine, flupenthixol, haloperidol and zucklopenthixol)and four second generation antipsychotics (aripiprazole, olanzapine, risperidone and paliperidone). It focuses especially on thetreatment initiation and dosage regimen. Basic advantages and disadvantages of depot formulation are discussed as well as itsefficacy in the prevention of relapse and the risk of adverse-events compared to oral formulation of antipsychotics.

Could pregabaline be effective medication in treatment of depressive disorder?

MUDr. Miroslav Sekot

Psychiatr. praxi 2017; 18(3)  

Pregabalin belongs to a group of antiepileptics and it is indicated for the treatment of generalized anxiety disorder and neuropaticpain. Although the antidepressant effect of pregabalin has not been proven, pregabalin can positively affect the mood of patientswith pain syndromes of various etiologies. Two case studies of pregabalin treatment in patients with depressive symptomatologyare described in this article.

Current trends in treatment of anxiety disorders

MUDr. Eliška Nosková, MUDr. Pavla Stopková, Ph.D., MUDr. Antonín Šebela

Psychiatr. praxi 2017; 18(3): 106-113 | DOI: 10.36290/psy.2017.020  

Anxiety disorders are a group of mental disorders, characterised by significant feelings of anxiety, usually accompanied by physicalsymptoms. Anxiety is induced either by specific and well-defined situations, or occurs without any apparent stimulus. In ourpaper, we review current trends and treatment guidelines of pharmacotherapy, psychotherapy, and additional evidence-basedtherapeutic interventions. Primarily, we focus on the most common disorders, such as social anxiety disorder, agoraphobia, panicdisorder, generalized anxiety disorder and specific phobias. Moreover, we also discuss briefly other disorders, e. g. obsessive–compulsivedisorder...

Novel trends in treatment of obsessive-compulsive disorder

MUDr. Pavla Stopková, Ph.D.

Psychiatr. praxi 2017; 18(3): 114-119 | DOI: 10.36290/psy.2017.021  

The aim of this paper is to summarize current treatments of obsessive-compulsive disorder (OCD) and to describe novel therapeuticalstrategies in the fields of pharmacotherapy, psychotherapy, stimulation, and neurosurgery. The use of SSRI antidepressantshas a well documented efficacy and growing evidence supports augmentation of SSRI with atypical antipsychotics. A promisingbut not yet established field is represented by glutaminergic modulators. Cognitive behavioral psychotherapy (CBT) is the mosteffective psychotherapy and evidence supports also the use of remote CBT – computer-based and on-line CBT. AcceptanceCommitment Therapy introduces a...

Trends in pharmacotherapy of unipolar depression

MUDr. Tomáš Novák, Ph.D.

Psychiatr. praxi 2017; 18(3): 120-124 | DOI: 10.36290/psy.2017.022  

Unipolar depression is a severe mental disease with high prevalence but response to treatment strategies remains unsatisfactory ina substantial part of patients. The development of new antidepressants and testing agents with antidepressive action represent themajor trends to improve this challenging situation. Current guidelines attempts to integrate new findings into recommendationsfor various situations in clinical practice. A paper provides a brief overview of current trends in pharmacotherapy of depression.

The issue of tardive dyskinesia, focusing on the therapeutic potential of tetrabenazine

prof. MUDr. Klára Látalová, Ph.D.

Psychiatr. praxi 2017; 18(3): 129-132 | DOI: 10.36290/psy.2017.024  

Wider use of atypical antipsychotics has reduced the prevalence and incidence of tardive dyskinesia (TD), but TD appearsto be a problem at times. Tardive dyskinesia is resistant to numerous treatment interventions. Clonazepam, amantadine,ginkgo biloba extract and tetrabenazine are more convincing results. Tardive dyskinesia persists even after discontinuationof antipsychotics and, moreover, after their discontinuation, signs of dyskinesia are often highlighted. All antipsychoticsto some extent antagonize dopamine, therefore their use will always be associated with the risk of TD even in modernpsychiatry. Interest in the possibility of targeted TD treatment...

The symptom of pain in psychotic patients

MUDr. Helena Kučerová

Psychiatr. praxi 2017; 18(3): 133-134 | DOI: 10.36290/psy.2017.025  

A lot of physicians have studied pain concernig somatic diseases. The author speaks about pain connected with psychiatric disorders,that has no organic base. The reason of this pain in psychotic patients (depressed, schizophrenic, schizoaffective) is thedisturbance of the whole personality, the outcome of which especially perception, thinking and mood are fault. Various typesof pains as illusions and hallucinations connected with dellusions of cancer or some infection are the leading symptomes ofhypochondric psychotic syndrome. The author presents a case of a male-patient 32 years old. After his first sex he started to bevery anxious and persuated...

Frontotemporal dementia

MUDr. Martin Vyhnálek1, 2

Psychiatr. praxi 2017; 18(3): 140-142  

The paper briefly summarizes the current clinical classification of frontotemporal dementias and basic recommendations for thediagnosis and treatment of this group of diseases.

Consumption of addictive sedatives and hypnotics in the Czech Republic and addiction on these medicines
from the consiliary psychiatric view

MUDr. Martin Konečný

Psychiatr. praxi 2017; 18(3): 135-139 | DOI: 10.36290/psy.2017.026  

The issue of sedative and hypnotic addictive drugs is generally perceived as serious in the Czech Republic. However there are norelevant data on the number of dependent patients and patients with substances misuse. There are also no estimates of consumptionof individual preparations and all benzodiazepines and Z-hypnotics as the only group corresponding to ICD-10 diagnosesunder F13. In this article, I attempted to make a rough estimate of individuals with addiction or misuse of sedatives or hypnoticson the basis of probable consumption derived from data on deliveries of individual preparations. The results were compared withdata from other countries....